In a first-of-its-kind human trial, researchers transplanted iPS-cell-derived dopaminergic progenitors into patients with Parkinson’s disease and observed promising motor improvements with no serious safety concerns over 24 months. The therapy showed increased dopamine synthesis without tumor formation or graft-induced dyskinesia.